CRESP 25

Anemia

Description
Shipping Options
Customer Reviews

1. Definition & Mechanism

Generic Name: Darbepoetin Alfa (25 mcg/dose)
Class: Long-acting Erythropoiesis-Stimulating Agent (ESA)
Function: Stimulates red blood cell (RBC) production by binding to erythropoietin receptors in bone marrow.
Half-life: ~3× longer than recombinant erythropoietin (EPO), allowing less frequent dosing.

2. Importance & Clinical Use

Primary Indications:

✅ Chronic Kidney Disease (CKD) Anemia (Dialysis & non-dialysis) ✅ Chemotherapy-Induced Anemia (in non-myeloid cancers) ✅ HIV-associated anemia (for patients on AZT therapy)

Key Benefits:

Reduces need for blood transfusions
Improves fatigue, dyspnea, and quality of life
Dosed less frequently than EPO (weekly/biweekly vs. 2–3× weekly)

3. Dosage & Administration

Patient Group	Route	Initial Dose	Maintenance
CKD (Dialysis)	IV/SC	0.45 mcg/kg weekly	Adjust to maintain Hb 10–12 g/dL
CKD (Non-Dialysis)	SC	0.45 mcg/kg every 2–4 weeks	Monitor Hb monthly
Chemotherapy Anemia	SC	2.25 mcg/kg weekly or 500 mcg every 3 weeks	Hold if Hb >12 g/dL

⚠️ Critical Notes:

Never exceed Hb >12 g/dL (↑ risk of thrombosis).
Iron status must be checked (co-administer iron if deficient).

4. Side Effects

Common (≥10%):

Hypertension (↑ BP)
Headache, dizziness
Injection-site pain
Nausea, diarrhea

Serious (Monitor Closely):

Thrombosis (DVT, stroke, MI) – *Highest risk if Hb >12 g/dL*
Pure Red Cell Aplasia (PRCA) – Rare antibody-mediated RBC failure
Seizures (in CKD patients)
Severe allergic reactions (rash, angioedema)

5. Storage & Handling

Temperature: Refrigerate at 2–8°C (do not freeze).
Light Sensitivity: Keep in original carton.
Shaking: Avoid – causes protein degradation.
Expiry: Discard unused portions (single-use vial).

6. Contraindications & Warnings

❌ Do NOT use in:

Uncontrolled hypertension
Pure Red Cell Aplasia (PRCA) post-ESA therapy
Hemoglobinopathy (e.g., sickle cell anemia) without concomitant transfusions

⚠️ Black Box Warning (FDA):

↑ Risk of death, MI, stroke, thrombosis if Hb >12 g/dL.
Cancer patients: ESA use may ↓ survival in some malignancies.

7. Conclusion

CRESP 25 (Darbepoetin Alfa) is a potent ESA for anemia in CKD and chemotherapy patients, offering convenient dosing but requiring strict Hb monitoring to avoid life-threatening complications. Must be prescribed by specialists with regular follow-up.

Need details on:

Cost comparison (vs. EPO or biosimilars)?
Guidelines for dose adjustments?
Management of ESA resistance?

1. Definition & Mechanism

Generic Name: Darbepoetin Alfa (25 mcg/dose)
Class: Long-acting Erythropoiesis-Stimulating Agent (ESA)
Function: Stimulates red blood cell (RBC) production by binding to erythropoietin receptors in bone marrow.
Half-life: ~3× longer than recombinant erythropoietin (EPO), allowing less frequent dosing.

2. Importance & Clinical Use

Primary Indications:

✅ Chronic Kidney Disease (CKD) Anemia (Dialysis & non-dialysis)
✅ Chemotherapy-Induced Anemia (in non-myeloid cancers)
✅ HIV-associated anemia (for patients on AZT therapy)

Key Benefits:

Reduces need for blood transfusions
Improves fatigue, dyspnea, and quality of life
Dosed less frequently than EPO (weekly/biweekly vs. 2–3× weekly)

3. Dosage & Administration

Patient Group	Route	Initial Dose	Maintenance
CKD (Dialysis)	IV/SC	0.45 mcg/kg weekly	Adjust to maintain Hb 10–12 g/dL
CKD (Non-Dialysis)	SC	0.45 mcg/kg every 2–4 weeks	Monitor Hb monthly
Chemotherapy Anemia	SC	2.25 mcg/kg weekly or 500 mcg every 3 weeks	Hold if Hb >12 g/dL

⚠️ Critical Notes:

Never exceed Hb >12 g/dL (↑ risk of thrombosis).
Iron status must be checked (co-administer iron if deficient).

4. Side Effects

Common (≥10%):

Hypertension (↑ BP)
Headache, dizziness
Injection-site pain
Nausea, diarrhea

Serious (Monitor Closely):

Thrombosis (DVT, stroke, MI) – *Highest risk if Hb >12 g/dL*
Pure Red Cell Aplasia (PRCA) – Rare antibody-mediated RBC failure
Seizures (in CKD patients)
Severe allergic reactions (rash, angioedema)

5. Storage & Handling

Temperature: Refrigerate at 2–8°C (do not freeze).
Light Sensitivity: Keep in original carton.
Shaking: Avoid – causes protein degradation.
Expiry: Discard unused portions (single-use vial).

6. Contraindications & Warnings

❌ Do NOT use in:

Uncontrolled hypertension
Pure Red Cell Aplasia (PRCA) post-ESA therapy
Hemoglobinopathy (e.g., sickle cell anemia) without concomitant transfusions

⚠️ Black Box Warning (FDA):

↑ Risk of death, MI, stroke, thrombosis if Hb >12 g/dL.
Cancer patients: ESA use may ↓ survival in some malignancies.

7. Conclusion

Need details on:

Cost comparison (vs. EPO or biosimilars)?
Guidelines for dose adjustments?
Management of ESA resistance?

Shipping Options –

We offer a variety of shipping options, including Express Mail Service (EMS), USPS, DHL, FedEx, TNT, UPS, Aramex, Air Cargo, and sea freight.

Terms and Conditions –

Bulk Orders: You are responsible for any local import duties and taxes in your country.

For Patients: When ordering prescription medicines for personal use, or for a friend or relative, a valid medical practitioner’s script or prescription is required.

Return and Refund Policy: Due to the nature of our products, we cannot accept returns or exchanges once a purchase is made. However, in the event of non-delivery, you are eligible for either a 100% refund or a reshipment of your order.

Description
Reviews (0)

1. Definition & Mechanism

Generic Name: Darbepoetin Alfa (25 mcg/dose)
Class: Long-acting Erythropoiesis-Stimulating Agent (ESA)
Function: Stimulates red blood cell (RBC) production by binding to erythropoietin receptors in bone marrow.
Half-life: ~3× longer than recombinant erythropoietin (EPO), allowing less frequent dosing.

2. Importance & Clinical Use

Primary Indications:

✅ Chronic Kidney Disease (CKD) Anemia (Dialysis & non-dialysis)
✅ Chemotherapy-Induced Anemia (in non-myeloid cancers)
✅ HIV-associated anemia (for patients on AZT therapy)

Key Benefits:

Reduces need for blood transfusions
Improves fatigue, dyspnea, and quality of life
Dosed less frequently than EPO (weekly/biweekly vs. 2–3× weekly)

3. Dosage & Administration

Patient Group	Route	Initial Dose	Maintenance
CKD (Dialysis)	IV/SC	0.45 mcg/kg weekly	Adjust to maintain Hb 10–12 g/dL
CKD (Non-Dialysis)	SC	0.45 mcg/kg every 2–4 weeks	Monitor Hb monthly
Chemotherapy Anemia	SC	2.25 mcg/kg weekly or 500 mcg every 3 weeks	Hold if Hb >12 g/dL

⚠️ Critical Notes:

Never exceed Hb >12 g/dL (↑ risk of thrombosis).
Iron status must be checked (co-administer iron if deficient).

4. Side Effects

Common (≥10%):

Hypertension (↑ BP)
Headache, dizziness
Injection-site pain
Nausea, diarrhea

Serious (Monitor Closely):

Thrombosis (DVT, stroke, MI) – *Highest risk if Hb >12 g/dL*
Pure Red Cell Aplasia (PRCA) – Rare antibody-mediated RBC failure
Seizures (in CKD patients)
Severe allergic reactions (rash, angioedema)

5. Storage & Handling

Temperature: Refrigerate at 2–8°C (do not freeze).
Light Sensitivity: Keep in original carton.
Shaking: Avoid – causes protein degradation.
Expiry: Discard unused portions (single-use vial).

6. Contraindications & Warnings

❌ Do NOT use in:

Uncontrolled hypertension
Pure Red Cell Aplasia (PRCA) post-ESA therapy
Hemoglobinopathy (e.g., sickle cell anemia) without concomitant transfusions

⚠️ Black Box Warning (FDA):

↑ Risk of death, MI, stroke, thrombosis if Hb >12 g/dL.
Cancer patients: ESA use may ↓ survival in some malignancies.

7. Conclusion

Need details on:

Cost comparison (vs. EPO or biosimilars)?
Guidelines for dose adjustments?
Management of ESA resistance?

Reviews

There are no reviews yet.

Be the first to review “CRESP 25”

Description
Reviews (0)

1. Definition & Mechanism

Generic Name: Darbepoetin Alfa (25 mcg/dose)
Class: Long-acting Erythropoiesis-Stimulating Agent (ESA)
Function: Stimulates red blood cell (RBC) production by binding to erythropoietin receptors in bone marrow.
Half-life: ~3× longer than recombinant erythropoietin (EPO), allowing less frequent dosing.

2. Importance & Clinical Use

Primary Indications:

✅ Chronic Kidney Disease (CKD) Anemia (Dialysis & non-dialysis)
✅ Chemotherapy-Induced Anemia (in non-myeloid cancers)
✅ HIV-associated anemia (for patients on AZT therapy)

Key Benefits:

Reduces need for blood transfusions
Improves fatigue, dyspnea, and quality of life
Dosed less frequently than EPO (weekly/biweekly vs. 2–3× weekly)

3. Dosage & Administration

Patient Group	Route	Initial Dose	Maintenance
CKD (Dialysis)	IV/SC	0.45 mcg/kg weekly	Adjust to maintain Hb 10–12 g/dL
CKD (Non-Dialysis)	SC	0.45 mcg/kg every 2–4 weeks	Monitor Hb monthly
Chemotherapy Anemia	SC	2.25 mcg/kg weekly or 500 mcg every 3 weeks	Hold if Hb >12 g/dL

⚠️ Critical Notes:

Never exceed Hb >12 g/dL (↑ risk of thrombosis).
Iron status must be checked (co-administer iron if deficient).

4. Side Effects

Common (≥10%):

Hypertension (↑ BP)
Headache, dizziness
Injection-site pain
Nausea, diarrhea

Serious (Monitor Closely):

Thrombosis (DVT, stroke, MI) – *Highest risk if Hb >12 g/dL*
Pure Red Cell Aplasia (PRCA) – Rare antibody-mediated RBC failure
Seizures (in CKD patients)
Severe allergic reactions (rash, angioedema)

5. Storage & Handling

Temperature: Refrigerate at 2–8°C (do not freeze).
Light Sensitivity: Keep in original carton.
Shaking: Avoid – causes protein degradation.
Expiry: Discard unused portions (single-use vial).

6. Contraindications & Warnings

❌ Do NOT use in:

Uncontrolled hypertension
Pure Red Cell Aplasia (PRCA) post-ESA therapy
Hemoglobinopathy (e.g., sickle cell anemia) without concomitant transfusions

⚠️ Black Box Warning (FDA):

↑ Risk of death, MI, stroke, thrombosis if Hb >12 g/dL.
Cancer patients: ESA use may ↓ survival in some malignancies.

7. Conclusion

Need details on:

Cost comparison (vs. EPO or biosimilars)?
Guidelines for dose adjustments?
Management of ESA resistance?

Reviews

There are no reviews yet.

Be the first to review “CRESP 25”

Medical Disclaimer

Anteka Pharmacy primary intention is to ensure that its consumers get information that is reviewed by experts, accurate and trustworthy. The information and contents of this website are for informational purposes only. They are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of your doctor and discuss all your queries related to any disease or medicine. Do not disregard professional medical advice or delay in seeking it because of something you have read on Anteka Pharmacy. Our mission is to support, not replace, the doctor-patient relationship.